Orexo ABORXOF 34 Return-on-Tangible-Equity is -125.17% as of Mar. 2026. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 899 Drug Manufacturers companies, Orexo AB ranks better than 94.77% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orexo AB's annualized net income for the quarter that ended in Mar. 2026 was $-57.48 Mil. Orexo AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $45.92 Mil. Therefore, Orexo AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -125.17%.
The historical rank and industry rank for Orexo AB's Return-on-Tangible-Equity or its related term are showing as below:
ORXOF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -459.51 Med: 16.22 Max: 1310.46
Current: 1310.46
During the past 13 years, Orexo AB's highest Return-on-Tangible-Equity was 1,310.46%. The lowest was -459.51%. And the median was 16.22%.
ORXOF's Return-on-Tangible-Equity is ranked better than 94.77% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.68
vs ORXOF: 1310.46
Orexo AB (OTCPK:ORXOF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Orexo AB Return-on-Tangible-Equity Related Terms
Orexo AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Orexo AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORXOF vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Orexo AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -125.17% mean?
Orexo AB (ORXOF) has a Return-on-Tangible-Equity of -125.17% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orexo AB and its competitors. According to the industry distribution chart, Orexo AB ranks #47 out of 899 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Orexo AB's Return-on-Tangible-Equity too high?
Orexo AB's current Return-on-Tangible-Equity is -125.17%. Based on the distribution chart, Orexo AB ranks #47 out of 899 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #47 out of 899 companies for Return-on-Tangible-Equity. This places Orexo AB in the top 5% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.68, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Return-on-Tangible-Equity is -125.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Return-on-Tangible-Equity is -125.17%. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Return-on-Tangible-Equity is -125.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
Return-on-Tangible-Equity: -125.17%
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
